

d) a pseudopeptide homologous to a peptide fragment of extracellular or cytoplasmic P95/nucleolin,

e) a pseudopeptide homologous to a peptide fragment of P40/PHAPII, and

f) a pseudopeptide homologous to a peptide fragment of P30/PHAPI.

H 2  
G 2  
6. (Amended) The inhibitor molecule according to any one of claims 2 to 5, which comprises an amino acid sequence chosen from:

- the sequence beginning at the amino acid in position 22 and ending at the amino acid in position 44 of SEQ ID NO: 22;

- the sequence beginning at the amino acid in position 143 and ending at the amino acid in position 171 of SEQ ID NO: 22;

- the sequence beginning at the amino acid in position 185 and ending at the amino acid in position 209 of SEQ ID NO: 22; and

- the sequence beginning at the amino acid in position 234 and ending at the amino acid in position 271 of SEQ ID NO: 22.

H 4  
G 3  
13. (Twice Amended) A composition comprising an inhibitor molecule according to any one of claims 2, 4 to 6, or 9 to 10, in combination with at least a second compound, wherein the second compound is an anti-HIV molecule.

Please add new claim 24, as follows:

24. A composition comprising an inhibitor molecule according to any one of claims 2, 4 to 6, or 9 to 10, further comprising at least a second compound.

FINNEGAN  
HENDERSON  
FARA-BOW  
GARRETT &  
DUNNE LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com